WHO. Measuring quality of life. WHO-QOL. 1997. http://www.who.int/mental_health/media/68.pdf. Accessed 21 May 2015.
Mamo G, Chelkeba L, Chanie T. Health-related quality of life among people living with human immunodeficiency virus on highly active antiretroviral therapy in Ethiopia: PROQOL-HIV based survey Tsegaye Melaku. Patient Relat Outcome Meas. 2020. https://doi.org/10.2147/PROM.S239429.
Pereira M, Canavarro MC. Gender and age differences in quality of life and the impact of psychopathological symptoms among HIV-infected patients. AIDS Behav. 2011;15(8):1857–69. https://doi.org/10.1007/s10461-011-9928-8.
Kharsany ABM, Karim QA. HIV infection and AIDS in sub-Saharan Africa: current status, challenges and opportunities. Open AIDS J. 2016;10(1):34–48. https://doi.org/10.2174/1874613601610010034.
Mutabazi-Mwesigire D, Katamba A, Martin F, Seeley J, Wu AW. Factors that affect quality of life among people living with HIV attending an urban clinic in Uganda: a cohort study. PLoS ONE. 2015;10(6): e0126810. https://doi.org/10.1371/journal.pone.0126810.
Arjun BY, Unnikrishnan B, Ramapuram JT, Thapar R, Mithra P, Kumar N, et al. Factors influencing quality of life among people living with HIV in coastal South India. J Int Assoc Provid AIDS Care. 2017;16(3):247–53. https://doi.org/10.1177/2325957415599213.
Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antivir Res. 2010;85(1):25–33. https://doi.org/10.1016/j.antiviral.2009.10.007.
Jagannath V, Unnikrishnan B, Hegde S, Ramapuram JT, Rao S, Achappa B, et al. Association of depression with social support and self-esteem among HIV positives. Asian J Psychiatry. 2011;4(4):288–92. https://doi.org/10.1016/j.ajp.2011.10.006.
Bajunirwe F, Tisch DJ, King CH, Arts EJ, Debanne SM, Sethi AK. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. AIDS Care. 2009;21(3):271–9. https://doi.org/10.1080/09540120802241863.
Mafirakureva N, Dzingirai B, Postma MJ, Van HM, Khoza S. Health-related quality of life in HIV/AIDS patients on antiretroviral therapy at a tertiary care facility in Zimbabwe. AIDS Care. 2016;28(7):904–12. https://doi.org/10.1080/09540121.2016.1173639.
Degroote S, Vogelaers DP, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, et al. Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study. J Int AIDS Soc. 2013;16(1):18643. https://doi.org/10.7448/IAS.16.1.18643.
Glass TR, De GS, Weber R, Vernazza PL, Rickenbach M, Furrer H, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients the Swiss HIV cohort study. J AIDS. 2006;41(3):385–92. https://doi.org/10.1097/01.qai.0000186371.95301.52.
Ssonko M, Stanaway F, Mayanja HK, Namuleme T, Cumming R, Kyalimpa JL, et al. Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda. BMC Geriatr. 2018;18:125. https://doi.org/10.1186/s12877-018-0817-0.
Chary A, Nguyen NN, Maiton KHM. A review of drug-drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017;10(12):1329–52. https://doi.org/10.1080/17512433.2017.1377610.
Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa—a primary data analysis. Cost Eff Resour Alloc. 2006;4:1–14. https://doi.org/10.1186/1478-7547-4-20.
Silva ACDO, Reis RK, Nogueira JA, Gir E. Quality of life, clinical characteristics and treatment adherence of people living with HIV/AIDS. Rev Lat Am Enfermagem. 2014;22(6):994–1000. https://doi.org/10.1590/0104-1169.3534.2508.
Luszczynska A, Sarkar Y, Knoll N. Received social support, self-efficacy, and finding benefits in disease as predictors of physical functioning and adherence to antiretroviral therapy. Patient Educ Couns. 2007;66(1):37–42. https://doi.org/10.1016/j.pec.2006.10.002.
Pokhrel KN, Pokhrel KG, Neupane SR. Harmful alcohol drinking among HIV-positive people in Nepal : an overlooked threat to anti-retroviral therapy adherence and health-related quality of life threat to anti-retroviral therapy adherence and health-related quality of life. Glob Health Action. 2018;11(1):1441783. https://doi.org/10.1080/16549716.2018.1441783.
Levi-minzi MA, Surratt HL. HIV stigma among substance abusing people living with HIV/AIDS: implications for HIV treatment. AIDS Patient Care STDS. 2014;28(8):442–51. https://doi.org/10.1089/apc.2014.0076.
Earnshaw VA. Stigma, discrimination and living with HIV/AIDS. Dordrecht: Springer; 2013. p. 23–38. https://doi.org/10.1007/978-94-007-6324-1.
Gebremichael DY, Hadush KT, Kebede EM, Zegeye RT. Gender difference in health related quality of life and associated factors among people living with HIV/AIDS attending anti-retroviral therapy at public health facilities, western Ethiopia: comparative cross sectional study. BMC Public Health. 2018;18(1):537. https://doi.org/10.1186/s12889-018-5474-x.
Choi SW, Podrabsky T, Mckinney N, Schalet BD, Cook KF, Cella D, et al. Prosetta stone® analysis report a Rosetta stone for patient reported outcomes promis physical function and neuro-QOL mobility. http://www.prosettastone.org/LinkingTables1/Linking%20tables%20vol1/PROMIS%20Physical%20Function%20and%20NeuroQOL%20Mobility%20Full%20Report.pdf. Accessed 22 May 2019.
Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, Chequer P, Teixeira PRHN. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS. 2003;17(11):1675–82.
Burgoyne RW, Tan DHS. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother. 2008;61:469–73.
Torres TS, Harrison LJ, La RAM, Cardoso SW, Zheng L, Ngongondo M, et al. Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS. 2017;32(5):583–93.
Keiser O, Tweya H, Boulle A, Braitstein P, Schechter M, Brinkhof MWG, Dabis F, Tuboi S, Sprinz E, Pujades-Rodriguez M, Calmy A, Kumarasamy N, Nash D, Jahn A, Macphail P, Lüthy R, Wood R, Egger M. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23(14):1867–74. https://doi.org/10.1097/QAD.0b013e32832e05b2.
Venter WDF, Moorhouse M, Sokhela S, Serenata C, Akpomiemie G, Qavi A, et al. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019. https://doi.org/10.1016/S2352-3018(19)30081-5.
Group ACT. Division of AIDS table for grading the severity of adult and pediatric adverse events. … Allergy Infect Dis Div AIDS. 2004;(August):1–21.
Wu AW. ACTG QOL 601–602 health survey manual: adult AIDS Clin Trials Gr. 1998.
Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. AIDS Patient Care STDS. 2015;29(3):111–6. https://doi.org/10.1089/apc.2014.0255.
Hurley AE, Scandura TA, Schriesheim CA, Brannick MT, Seers A, Vandenberg RJ, et al. Exploratory and confirmatory factor analysis: guidelines, issues, and alternatives. J Organ Behav. 1997;18(6):667–83.
Harrington D. Confirmatory factor analysis. Pocket guides to social work. Oxford: Oxford University Press; 2009.
Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodnessof-fit measures. Methods Psychol Res Online. 2003;8(2):23–74.
Hu LT, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6(1):1–55.
Kaiser HF. The application of electronic computers to factor analysis. Educ Psychol Meas. 1960;20:141–51.
Vandenberg RJ. Statistical and methodological myths and urban legends. Organ Res Methods. 2006;9(2):194–201.
Bücher A, Dette H. Assessing model fit in structural equation modeling using appropriate test statistics. J Multivar Anal. 2010;101(3):749–63. https://doi.org/10.1016/j.jmva.2009.09.014.
Gakhar H, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs. 2013;73(7):651–72.
Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antivir Res. 2010;85:201–9.
Gupta S, Knight AG, Losso BY, et al. Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance. Antivir Res. 2012;95:19–29.
Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS Res Palliat Care. 2012;4:117–24.
Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al. Ageing with HIV: medication use and risk for potential drug–drug interactions. J Antimicrob Chemother. 2011;66:2107–11.
Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV cohort study. Antivir Ther. 2010;15:413–23.
Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard P-M, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679–88.
Molina J-M, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646–55.
Rodriguez-Penney AT, Iudicello JE, Riggs PK, Doyle K, Ellis RJ, Letendre SL, et al. Co-morbidities in persons infected with HIV : increased burden with older age and negative effects on health-related quality of life. PLoS ONE. 2013;27(1):5–16.
Wouters E, Heunis C, van Rensburg D, Meulemans H. Physical and emotional health outcomes after 12 months of public-sector antiretroviral treatment in the Free State Province of South Africa: a longitudinal study using structural equation modelling. BMC Public Health. 2009;9(1):103. https://doi.org/10.1186/1471-2458-9-103.
Bergenstrom AM, Abdul-Quader AS. Injection drug use, HIV and the current response in selected low-income and middle-income countries. AIDS. 2010;24(3):S20–9.
Thanh DC, Moland KM, Fylkesnes K. The context of HIV risk behaviours among HIV-positive injection drug users in Viet Nam: moving toward effective harm reduction. BMC Public Health. 2009;9:98.